- SOHM Inc. (SHMN, Financial) is expanding its ABBIE genome editing program to support growing NGS validation needs.
- The company is enhancing its AI-enabled ABBIE platform for next-generation gene editing applications.
- SOHM will present its research at the American Society of Gene and Cell Therapy Conference in May 2025.
SOHM Inc. (OTC PINK: SHMN), a prominent player in the biopharmaceutical sector, has announced a strategic expansion of its ABBIE genome editing and cell engineering program. This initiative will take place at the company's Carlsbad facility and UACI labs, aiming to fulfill the rising validation requirements in Next-Generation Sequencing (NGS). This move aligns with the growing demand for engineered mouse models and cell lines vital for drug development, gene therapy, and immunotherapy.
The expansion aims to bolster SOHM's capabilities by enhancing their AI-enabled ABBIE platform, supporting advanced applications in next-generation gene editing. According to the company, these advancements will significantly contribute to their leadership in precision medicine, focusing on safe, efficient, and targeted gene editing solutions.
SOHM will also showcase its innovative research at the American Society of Gene and Cell Therapy Conference, scheduled from May 13-17, 2025, in New Orleans, LA. The presentation, entitled "ABBIE Gene Editing: A Breakthrough in Precise, Replicable, and Traceable Genomic Integration," will highlight the company's cutting-edge breakthroughs in genomic technologies.
Further details about SOHM's presentation will be released as the event approaches. This development emphasizes the company's commitment to advancing genome editing technologies and strategic collaborations in the field of gene therapy.
